At Scientia Vascular, we believe that without access, therapy can not exist. Through cutting-edge innovation, we’re answering our calling to radically disrupt the way diseases of the brain are treated. Our teams have been at the forefront of neurovascular systems, pushing beyond established boundaries to deliver the products physicians and patients need most.
Scientia strives to serve humanity with medical solutions that disrupt the status quo. Through advanced technology and boundless creativity, we empower physicians to improve patient outcomes and redefine the possibilities of healthcare. We collaborate with medical professionals and employees in a shared mission to drive transformative change in the world of patient care.
At Scientia Vascular, our team constantly thinks about what patients need. Collectively, our staff brings an extensive background and knowledge of clinical perspectives; manufacturing; and mechanical, biomedical, and electrical engineering to focus on new product development that meets physician and patient needs. Our management team is composed of professionals from leading companies in the endovascular field who have played important roles leading to successful mergers and acquisitions, including Precision Vascular Systems by Boston Scientific.
Scientia is founded in Reno, Nevada, by CEO John Lippert. Like some of the other great contemporary tech companies we've come to know and love, our work began in a humble garage. Hailing from Reno, Nevada, the next generation of microfabrication began paving the way for better access that allows for better therapies.
On the move
2013 Scientia relocates to Salt Lake City as the vibrant city began to bloom. With a rich pool of talent, an emerging medical technology sector heavily steeped in biological engineering, and an international airport ten minutes from the city center, Scientia knew to jump on the opportunity of planting roots in a beautiful city where work and play intertwine.
A first of many
Aristotle® 14 is cleared by the FDA for sale in the United States. A new generation of microfabrication, utilizing micromachining across the entirety of the nitinol tube of the microwire, is introduced to the market.
Aristotle® 18 gets the green light and launches in the United States with full market release in 2019. Momentum builds as physicians begin to see the possibilities of larger-diameter wires in the neurovascular space.
Aristotle® 24 enters the stage, changing the game when it comes to reliable access. Physicians experience the power of predictive response and optimized torque output combined with the softness of small microwires for the first time.
Vivo Capital recognizes Scientia Vascular’s potential, investing in the future of providing better, more reliable access for improved patient outcomes. With such investment, Scientia was given an increased ability to resource a thriving headquarters and manufacturing site for leading access to therapy.
The future is now
Scientia Vascular establishes a headquartered building with increased manufacturing capability. Scaling for success resulted in also needing additional warehousing space and clean room manufacturing capabilities, which were added to increase the ability to better serve patient needs.
Aristotle® Colossus disrupts the market more than any other technology within the Scientia portfolio as the first ever 0.035-inch neurovascular-indicated macrowire. When paired with 0.038-inch inner-diameter catheters, it’s designed to produce increased stability for distal navigation with flexibility needed for safe interactions with the anatomy. These features make for a powerful tool when navigating tortuous anatomy and treating complex cases.
Request a demo
For more of a hands on experience, schedule a demonstration of our products with one of our team members today!